Publication at Third Faculty of Medicine |
2017
Abstract
Vemurafenib is a selective inhibitor of the BRAF-kinase approved for the treatment of metastatic melanoma harboring BRAF mutation. Skin toxicity, including maculopapular exanthema, photosensitivity and keratoacanthoma, are the most common treatment-related adverse events of vemurafenib, affecting more than 90% of patients.
It rarely presents with intense severity, with less than 1% of grade-4 toxicities reported in clinical trials.